Schedule 13G ownership disclosure
Vistagen Therapeutics Inc
Common Stock, par value $0.001 per share ("Shares") · CUSIP: 92840H400
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- StemPoint Capital LP
Shares: 2,328,492.00 · Class: 8.2%
- StemPoint Capital Management GP LLC
Shares: 2,328,492.00 · Class: 8.2%
- Michelle Ross
Shares: 2,328,492.00 · Class: 8.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-013829
- Form type
- SCHEDULE 13G/A
- Filer
- STEMPOINT CAPITAL LP
- CIK
- CIK 1952142
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership